We identified bromocriptine in a blind screen for CREBZF inhibitors and showed that it partially prevents obesity‐related inflammatory and metabolic disorders by inhibiting CREBZF. This evidence concerns the gene CREBZF and obesity due to melanocortin 4 receptor deficiency.